(RTTNews) - H. Lundbeck A/S (HLBBF) announced headline results from the Phase IV THRIVE trial evaluating eptinezumab, an investigational humanised monoclonal antibody administered intravenously, in adults with migraine who had an inadequate response to one prior CGRP-targeting pr
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.